Previous 10 | Next 10 |
Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q1 2021 Earnings Call Feb 5, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Meridian Bioscience Inc (VIVO) Q1 2021 Earnings Call Transcript
Meridian Bioscience, Inc. (VIVO) Q1 2021 Earnings Conference Call February 05, 2021, 10:00 ET Company Participants Charles Wood - VP, Corporate Strategy, Business Development & IR John Kenny - President, CEO & Director Bryan Baldasare - EVP, CAO, CFO & Secretary Conference Call Pa...
Meridian Bioscience (VIVO): Q1 Non-GAAP EPS of $0.66 beats by $0.24; GAAP EPS of $0.62 beats by $0.20.Revenue of $92.9M (+95.9% Y/Y) beats by $4.57M.Press Release For further details see: Meridian Bioscience EPS beats by $0.24, beats on revenue
CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020. First Quarter 2021 Highlights (Comparison to First Quarter Fiscal 2020): Consolidated net revenues of $92.9...
High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...
Meridian Bioscience ([[VIVO]] -0.7%) will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene platform after receiving a $5.5M award from the National Institute of Health ((NIH)) Rapid Acceleration of Diagnostics initiative and an additional...
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene ...
CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for manufa...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021. Jack Kenny, Chief Executive Officer, and...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...